Drug manufacturer JCR announced last month that it has submitted a marketing approval in Japan for JR-051, a proposed agalsidase beta biosimilar referenced on Fabrazyme.
Drug manufacturer JCR announced last month that it has submitted a marketing approval in Japan for JR-051, a proposed agalsidase beta biosimilar referenced on Fabrazyme. JCR developed the drug in partnership with Amicus Therapeutics and GlaxoSmithKline.
JR-051, like its reference, is a recombinant human alpha-galactosidase A enzyme replacement therapy that is used to treat Fabry’s disease (FD), a rare, inherited disorder that affects 1 in 40,000 to 60,000 men (the disorder can also occur in women, though its prevalence is not known). The result of a mutation in the alpha-galactosidase A gene, patients with FD have a buildup of globotriaosylceramide in cells, which can adversely affect the functioning of the heart, kidneys, and other organs and lead to cardiac disease, stroke, renal failure, and early death.
According to a paper in Genetics in Medicine, the reference agalsidase beta, manufactured by Sanofi Genzyme, was subject to a global shortage in 2009 after a manufacturing process introduced viral contamination into the drug supply. During the shortage, patients were instructed by the European Medicines Agency (EMA) to reduce their dosages. An increased rate of serious adverse events associated with the drug was observed among patients who followed directions to reduce their doses, and the EMA subsequently recommended switching patients to other therapies.
The shortage posed such a dire risk for US patients with FD that patients petitioned the federal government to allow a Bayh-Dole “march-in” proceeding that would force Sanofi Genzyme to license its patent for the drug to additional drug makers. The National Institutes of Health determined that a march-in proceeding was not warranted, largely because a granting patent use rights to a third party would not solve the problem of the drug shortage in the short term, as clinical studies and regulatory approval would still be required before a biosimilar could be made available to patients in the United States.
Emergence of agalsidase beta biosimilars has the potential to prevent or mitigate the effects of any future shortages for this under-served patient population. Just as importantly, biosimilars have the potential to reduce the extraordinarily high cost of treatment associated with FD. In a report on specialty drugs spending, America’s Health Insurance Plans (AHIP) estimated that the originator agalsidase beta has an average wholesale price of over $300,000 per patient per year. A UK study on the cost effectiveness of enzyme-replacement therapies, including originator agalsidase beta, found that the cost to treat a patient with FD “exceeds the normal upper threshold for cost-effectiveness seen in NHS policy decisions by over six-fold,” but that the health system was left with “no option” but to provide the high-cost therapy.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.